This site is intended for health professionals only

At the heart of general practice since 1960

Read the latest issue online

Gold, incentives and meh

Concerns eased over PPIs and clopidogrel

By Nigel Praities

Proton pump inhibitors may not reduce activity of antiplatelet inhibitors such as clopidogrel after all.

An analysis of data from 13,000 patients found rates of cardiovascular death, stroke or heart attack were 11.8% in patients taking clopidogrel and a PPI and 12.2% for those just taking clopidogrel.

Patients in the prasugrel group on a PPI had a rate of cardiovascular death, stroke or heart attack of 10.2 %, compared with 9.7% for those not on a PPI.

Dr Michelle O'Donoghue, investigator in the TIMI research group at Brigham and Women's Hospital in Boston, said: ‘The current findings do not support the need to avoid PPI use in patients taking thienopyridines.'

The research was published online in The Lancet and presented at the European Society of Cardiology meeting in Barcelona, Spain, last weekend.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say